Home Cart Sign in  
Chemical Structure| 1223405-08-0 Chemical Structure| 1223405-08-0

Structure of Larotrectinib sulfate
CAS No.: 1223405-08-0

Chemical Structure| 1223405-08-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LOXO-101 sulfate blocks the ATP binding site of the TRK family of receptors with IC50 of 2 nM to 20 nM against TRKA, TRKB, and TRKC.

Synonyms: LOXO-101 sulfate; ARRY-470 sulfate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Larotrectinib sulfate

CAS No. :1223405-08-0
Formula : C21H24F2N6O6S
M.W : 526.51
SMILES Code : O=S(O)(O)=O.O=C(N1CC[C@H](O)C1)NC2=C3N=C(N4[C@@H](C5=CC(F)=CC=C5F)CCC4)C=CN3N=C2
Synonyms :
LOXO-101 sulfate; ARRY-470 sulfate
MDL No. :MFCD29472286
InChI Key :PXHANKVTFWSDSG-QLOBERJESA-N
Pubchem ID :67330085

Safety of Larotrectinib sulfate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Larotrectinib sulfate

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A375 cells 10 µM 16 hours Larotrectinib enhanced the sensitivity of A375 cells to IFNγ, increasing CXCL10 expression Nat Immunol. 2024 Feb;25(2):268-281.
SK-MEL-2 cells 10 µM 16 hours Larotrectinib enhanced the sensitivity of SK-MEL-2 cells to IFNγ, increasing CXCL10 expression Nat Immunol. 2024 Feb;25(2):268-281.
HEK293 cells 5 µM 2.5 minutes Assess the uptake of Larotrectinib in HEK293 cells, showing that OATP1A2 increased the uptake of Larotrectinib, while OATP1B1, OATP1B3, and OATP2B1 did not significantly increase its uptake Br J Pharmacol. 2020 Jul;177(13):3060-3074.
B16 cells 10 µM 24 hours Larotrectinib enhanced the sensitivity of B16 cells to IFNγ, increasing Stat1 activation and Cxcl10 production Nat Immunol. 2024 Feb;25(2):268-281.
COLO205 cells 300 nM 24 hours Lar significantly suppressed the proliferation and migration of COLO205 cells and inhibited the epithelial-mesenchymal transition (EMT) process J Cell Mol Med. 2022 Nov;26(21):5539-5550.
HCT116 cells 300 nM 24 hours Lar significantly suppressed the proliferation and migration of HCT116 cells and inhibited the epithelial-mesenchymal transition (EMT) process J Cell Mol Med. 2022 Nov;26(21):5539-5550.
MDCK-II cells 5 µM 8 hours Assess the transepithelial transport of Larotrectinib in MDCK-II cells, showing that Larotrectinib was avidly transported by hABCB1 and mAbcg2, and efficiently by hABCG2 Br J Pharmacol. 2020 Jul;177(13):3060-3074.
DU145 20 nM Overnight Larotrectinib significantly increased the expression of endogenous AGPS J Exp Clin Cancer Res. 2024 Jan 11;43(1):16.
22Rv1 20 nM Overnight Larotrectinib significantly increased the expression of endogenous AGPS J Exp Clin Cancer Res. 2024 Jan 11;43(1):16.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Genetically modified mouse models Oral 10 mg/kg Single dose, lasting 8 hours or 1 hour Assess the pharmacokinetic behavior of Larotrectinib in genetically modified mouse models, showing that ABCB1 and ABCG2 markedly limited the oral availability and brain accumulation of Larotrectinib, and OATP1A/1B and CYP3A also significantly affected its pharmacokinetics Br J Pharmacol. 2020 Jul;177(13):3060-3074.
Nude mice HCT116 xenograft model Intragastrically 20 mg/kg Twice daily for 3 weeks Lar significantly reduced tumour volume and weight in the HCT116 xenograft model and activated the AMPK/mTOR signalling pathway J Cell Mol Med. 2022 Nov;26(21):5539-5550.
Mice B16 melanoma model Oral 200 mg/kg Daily for 60 days Larotrectinib combined with immunotherapy significantly improved the complete remission rate of melanoma, achieving a CR rate of >60% at the three-month mark, with 40% of animals achieving durable cure Nat Immunol. 2024 Feb;25(2):268-281.
SCID mice Subcutaneous tumor xenograft model Subcutaneous injection 300 mg/kg Every 24 hours for 28 days Larotrectinib in combination with ML210 significantly inhibited tumor growth J Exp Clin Cancer Res. 2024 Jan 11;43(1):16.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.50mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

References

 

Historical Records

Categories